Medtronic plans to separate its diabetes business, which generated $2.5 billion in sales in fiscal year 2024, into a stand-alone company with approximately 8,000 employees, according to a Wall Street Journal report. The new entity will be led by Que Dallara and based in Northridge, California, with the separation expected to be completed within 18 months, as Medtronic aims to address previous FDA product safety concerns.
Medtronic (MDT.N) reportedly intends to separate its diabetes business into a stand-alone company, according to the Wall Street Journal. This new entity, projected to be led by Que Dallara, the current head of Medtronic's diabetes division, will have approximately 8,000 employees and is anticipated to complete its separation within 18 months. The diabetes business, which generated $2.5 billion in sales in the fiscal year ended April 2024, has been undergoing turnaround efforts, notably after receiving a U.S. Food and Drug Administration warning letter in 2021 regarding product safety issues. This strategic restructuring could enable Medtronic to concentrate on its other core medical technology segments, while allowing the new, independent diabetes company to dedicate its focus to resolving regulatory matters and pursuing specific growth opportunities in its market. The reported neutral sentiment (0.1 score) and low market impact score (0.3) associated with this news suggest investors may be adopting a cautious stance, awaiting further clarification on the financial and operational details of the proposed spin-off.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
